Twenty new blog posts, interviews with prominent scientists, employee spotlights, research highlights, acquisitions and collaborations, certification, product launches, and a new CEO. What a year for Atlas Antibodies! Read all about it.
2021 was an excellent year for Atlas Antibodies, thanks to our talented teams, the researchers, and partners who share their businesses with us. Thank you for keeping up and for being part of our community! We kept you updated and informed with our blog and news throughout this challenging year. Now it's time for a recap! Let's look back at what we achieved together.
What got you interested in your research field? What is the importance of your research? What is the most exciting discovery you made? What was the biggest challenge in your discovery? These are some of the questions we asked for our Interview with a Scientist series.
By answering our questions, Dr. Erika von Euw talks about cell therapy. Dr. Eugenia Kuteeva discusses the development of monoclonal antibodies for neuroscience research. Dr. Valentina Bonetto shares her research on the neurodegenerative disease amyotrophic lateral sclerosis. Moreover, the Atlas Antibodies team shared bits of company life, and our CSO, Dr. Caroline Kampf, reviews Atlas Antibodies' journey and our 15th-anniversary celebrations.
You, inspiring researchers, are the heroes of our time. We are proud to be part of your journey, your discoveries, and your breakthroughs. Our shared knowledge leads to better ways to predict, prevent, diagnose, and treat diseases.
Through our Research Roundup series, we highlight some of your discoveries made in neuroscience, cancer, cell biology, and more using our antibodies. So how do our antibodies help you in your research? Let us know!
Other popular blogs
In our neuroscience-related blog posts, we wrote about the search for new biomarkers in ALS, the updated WHO CNS5 glioma classification together with a list of our newly released glioma markers, and more.
We highlighted three recent papers exploring diagnostic and prognostic cancer markers for our cancer-related blog posts. We also listed antibodies targeting ion channels as promising biomarkers in cancer and more.
Atlas Antibodies company highlights
In 2021 Atlas Antibodies launched 1500+ new monoclonal and polyclonal antibodies covering research areas such as cancer, cell biology, immunology, metabolism, neuroscience, transcriptional regulation, stem cells & developmental biology.
We acquired the UK company HistoCyte Laboratories Ltd., which produces innovative cell line control for IHC and the Swiss evitria, a world leader in transient recombinant antibody expression in CHO cells.
We have entered a collaboration agreement with T-Cure Biosciences, Inc. to develop, manufacture, and supply the monoclonal antibody CT83 (KK-LC-1) for diagnostic use (gastric, triple-negative breast cancer, cervical, and lung cancer, and other KK-LC-1 positive epithelial cancers).
Nille Klæbel has been appointed as Atlas Antibodies' new CEO! With her strong background in marketing and sales and knowledge of the life sciences, pharma and healthcare industries, Nille is highly equipped to lead the next essential steps in developing Atlas Antibodies into a global life sciences company.
Last but not least, we received the ISO 9001:2015 certification, which is the internationally recognized standard for a quality management system for organizing and continually improving business processes and efficiency.
Atlas Antibodies resources: find your answers online
Our website has a dedicated section where you can read, download, and share educational material such as white papers, infographics, protocols, and guides. In our Q&A section, you can also find support for troubleshooting. In 2021 we added new whitepapers exploring the Tumor Microenvironment and Cancer Immunity, Cancer Stem Cell Markers, GPCR Markers for Cancer Research, Glioma Markers, Neuroinflammation, and our catalog Atlas Antibodies in Neuroscience.
We have created infographics for different research areas with links to valuable resources and updated the protocols for using our antibodies in immunohistochemistry, immunofluorescence, and Western blot.
Please use our materials and pass them along to others for educational purposes!
Thank you for this fantastic year!
Follow us for inspiration, education, and updates!
See you in 2022!